Tag results:

Industry & Policy News

EBGLYSS® (Lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis

[Almirall, S.A.] Almirall S.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending the marketing authorization of EBGLYSS for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.

Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

[Medigene AG] Medigene AG announced that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein technology.

Human Trials of Artificial Wombs Could Start Soon. Here’s What You Need to Know

[Nature News] Researchers at the Children’s Hospital of Philadelphia are seeking approval for the first human clinical trials of the device they’ve been testing, named the Extra-uterine Environment for Newborn Development, or EXTEND. The team has emphasized that the technology is not intended — or able — to support development from conception to birth.

Neurobo Pharmaceuticals Doses First Patient in Its Phase IIA Clinical Trial Evaluating Da-1241 for the Treatment of NASH

[NeuroBo Pharmaceuticals] NeuroBo Pharmaceuticals, Inc. announced dosing of the first patient in its two-part, Phase IIa clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, for the treatment of nonalcoholic steatohepatitis (NASH).

Possible Misconduct Found in Papers from Italian Minister of Health

[Science Insider] An Italian newspaper has found duplicated images in eight cancer papers co-authored by the country's minister of health, Orazio Schillaci. Dr. Schillaci published the papers between 2018 and 2022 while working in the faculty of medicine of the University of Rome Tor Vergata.

Scientific Retractions May Become Easier to Spot As Retraction Watch Finds New Partner

[ScienceInsider] Retraction Watch, the influential website and database that tracks retractions in scholarly literature, is joining forces with another publishing nonprofit, Crossref, in hopes of helping researchers and journals flag articles that have been retracted and sustain the literature’s veracity.

Popular